Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Gout Market Report Overview
The gout market across the 7MM (the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $4.63 billion in 2022 and the market will grow at a CAGR of more than 9% from 2022 to 2032. The market growth is attributed to the entrance of novel urate-lowering therapy (ULTs) which will increase the treatment options for more challenging and severe types of gout. This, in turn, will also accelerate the patient pool. The surge in the patient pool will further lead to the gout market growth.
Gout Market Outlook, 2022-2032 ($ Billion)
Buy the Full Report to Know More About the Gout Market Forecast
Download a Free Sample Report
The gout market research report offers an overview of epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies for Gout market participants. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.
| Market Size (2022) | $4.63 billion |
| CAGR (2022-2032) | >9% |
| Key Countries (7MM) | · The US
· France · Germany · Italy · Spain · The UK · Japan |
| Key Drugs | · NSAIDs
· Colchicine · Oral Corticosteroids · Corticosteroid Injections · Anakinra (off-label) |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Gout Market Dynamics
The entry of eight novel entrants across the forecast period will provide a significant opportunity to address the need for long-term, efficacious therapies. The uptake of these therapies in the gout pipeline by physicians will be driven by clinical data demonstrating efficacy. If a novel ULT therapy can demonstrate significant efficacy in treating chronic gout cases in adults and elderly patients, it will obtain a large market share.
Buy the Full Report for Additional Insights into the Gout Market Dynamics
Download a Free Sample Report
Gout Market Segmentation by Country
The key countries in the gout market are the US, France, Germany, Italy, Spain, the UK, and Japan in 2022, the US accounted for the highest share of the gout market. The US’s market dominance is due to the higher price of pharmaceuticals in the country. Furthermore, the high diagnosed prevalence of gout in the country compared to the other major markets contributes to this growth.
Gout Market Analysis by Country, 2022 (%)
Buy the Full Report for More Country Insights into the Gout Market
Download a Free Sample Report
Gout Market Segmentation by Drug
The key drugs in the gout market are NSAIDs, Colchicine, Oral Corticosteroids, Corticosteroid Injections, and Anakinra (off-label), among others. In 2022, the Colchicine drug sales were the highest. Furthermore, several therapies are expected to launch in the later years of the forecast period. This includes dapansutrile, canakinumab (biosimilar), pegloticase (biosimilar), dotinurad (pediatric use), and pegadricase, among others.
Gout Market Analysis by Drug, 2022 (%)
Buy the Full Report for More Drug Insights into the Gout Market
Segments Covered in this Report
Gout Market Country Outlook ($ Billion, 2022-2032)
- The US
- France
- Germany
- Italy
- Spain
- The UK
- Japan
Gout Market Drug Outlook (%, 2022-2032)
- NSAIDs
- Colchicine
- Oral Corticosteroids
- Corticosteroid Injections
- Anakinra (off-label)
Scope
- Overview of gout, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized gout therapeutics market revenue in 7MM (US, 5EU, and Japan), the annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the gout therapeutics market.
- Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for gout treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 7MM gout therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model.
Forecast includes US, 5EU, and Japan [5EU (France, Germany, Italy, Spain, and the UK) were forecasted as one entity]
Forecasts cover 2022-2032.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the gout therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the gout therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Teijin Pharma Ltd
Fuji Yakuhin Co Ltd
Lipomed AG
Novartis AG
Swedish Orphan Biovitrum
LG Chem
Olatec Therapeutics
Shanton Pharma
Dyve Biosciences
Arthosi Therapeutics
InventisBio
Table of Contents
Frequently asked questions
-
What was the gout market size in 2022?
The gout market across the 7MM was valued at $4.63 billion in 2022.
-
What will the gout market growth rate be during the forecast period?
The gout market will register a CAGR of more than 9% from 2022 to 2032 in the seven major markets (7MM).
-
Which was the leading country in the 7MM in the gout market in 2022?
In 2022, the United States (US) dominated the gout market in the 7MM.
-
Which was the leading drug in the gout market in 2022?
The Colchicine drug sales were the highest in the gout market in 2022.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Gouty Arthritis (Gout) reports